BMS-986517

PreclinicalSmall molecule

Bristol-Myers Squibb

BMS-986517 is one of 5 small molecule programs targeting Solid Tumours. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumoursRecruiting

Solid TumoursPreclinical

Recruiting

Competition

Competitive Landscape

7 competitors in Solid Tumours

#DrugCompanyPhaseTrials

Hernexeos

Boehringer Ingelheim

Phase 2

1 2

Imjudo

AstraZeneca

Phase 1

1 3

Brigimadlin

Boehringer Ingelheim

Phase 2

1 4

IV Durvalumab

AstraZeneca

Phase 1

1 5

BMS-986517

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Solid Tumours

NCT07160725

Clinical

Trials by Indication[1]

Solid Tumours1 trial

A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy in Adult Participants With Advanced Solid Tumors

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07160725·315 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BMS-986517. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986517 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986517. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bristol-Myers Squibb

BMS-986517

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Solid Tumours1 trial

References

Drug Info

Quick Facts

Related News